World's Best Scientists 2026 revealed!
Bernard Zinman

Bernard Zinman

Award Badge
Medicine
Canada
2023

D-Index & Metrics

Medicine

D-Index
147
Citations
128611
World Ranking
1250
National Ranking
38

Bernard Zinman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Bernard Zinman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 849 publications — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Bernard Zinman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Bernard Zinman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 147 D-Index — 94th percentile

94% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Canada Leader Award

Overview

Bernard Zinman is affiliated with the University of Toronto in Canada and has contributed extensively to medical research, particularly in the fields of endocrinology, diabetes, and metabolism. Their work primarily focuses on diabetes treatment and management, with notable attention to pancreatic function, chronic kidney disease related to diabetes, and broader metabolism studies involving diabetes and cancer.

Their research spans a range of topics including:

  • Diabetes Treatment and Management
  • Pancreatic function and diabetes
  • Diabetes Management and Research
  • Metabolism, Diabetes, and Cancer
  • Gestational Diabetes Research and Management
  • Chronic Kidney Disease and Diabetes
  • Diet and metabolism studies

Zinman has published a significant number of articles in leading journals related to diabetes and metabolism. Frequent publication venues include:

  • Diabetes Obesity and Metabolism (21 publications)
  • Diabetes (17 publications)
  • Diabetes Care (16 publications)
  • UNC Libraries (10 publications)
  • Circulation (6 publications)

Key recent papers authored or co-authored by Zinman include:

  • Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER, 2021, published in Circulation
  • Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial, 2020, published in The Lancet Diabetes & Endocrinology
  • Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial, 2020, published in Kidney International
  • Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial, 2020, published in Journal of the American Society of Nephrology
  • Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers, 2022, published in Alzheimer's & Dementia Translational Research & Clinical Interventions

Their collaboration network includes frequent co-authors such as:

  • Christoph Wanner
  • Silvio E. Inzucchi
  • Jyothis T. George
  • Michaela Mattheus
  • David Fitchett

Zinman's research contributions are concentrated in the subfields of endocrinology, diabetes and metabolism, surgery, molecular biology, obstetrics and gynecology, and nephrology. The counts of publications across these subfields are considerable, showing a diverse research portfolio.

This profile reflects the work of a scientist deeply engaged in investigating complex interrelations between diabetes, kidney function, and metabolic disorders, often through clinical trials and large-scale analyses.

Best Publications

  • Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

    Bernard Zinman;Christoph Wanner;John M. Lachin;David Fitchett

  • Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

    David M. Nathan;Patricia A. Cleary;Jye Yu C Backlund;Saul M. Genuth

  • Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes

    David M. Nathan;John B. Buse;Mayer B. Davidson;Ele Ferrannini

  • Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

    Vlado Perkovic;Vlado Perkovic;Meg J. Jardine;Meg J. Jardine;Bruce Neal;Bruce Neal;Bruce Neal;Severine Bompoint

  • Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

    Kahn Se;Haffner Sm;Heise Ma;Herman Wh

  • International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes

    David M. Nathan;Beverly Balkau;Enzo Bonora;Knut Borch-Johnsen

  • Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals

    Hertzel C. Gerstein;Johannes F. E. Mann;Qilong Yi;Bernard Zinman

  • Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

    rosiglitazone Medication Trial Investigators;H C Gerstein;S Yusuf

  • Impaired fasting glucose and impaired glucose tolerance: implications for care.

    David M. Nathan;Mayer B. Davidson;Ralph A. DeFronzo;Robert J. Heine

  • Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

    Rury R. Holman;M. Angelyn Bethel;Robert J. Mentz;Vivian P. Thompson

  • [Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. (A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes)].

    D M Nathan;J В Buse;M В Davidson;R J Heine

  • Diabetic Retinopathy and Diabetic Macular Edema: Pathophysiology, screening, and novel therapies

    Thomas A. Ciulla;Armando G. Amador;Bernard Zinman

  • Liraglutide and Renal Outcomes in Type 2 Diabetes

    Johannes F.E. Mann;David D. Ørsted;Kirstine Brown-Frandsen;Steven P. Marso

  • Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

    Julio Rosenstock;Vlado Perkovic;Odd Erik Johansen;Mark E. Cooper

  • Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial

    David Fitchett;Bernard Zinman;Bernard Zinman;Christoph Wanner;John M. Lachin

  • Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

    D. M. Nathan;J. B. Buse;M. B. Davidson;E. Ferrannini

  • Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

    Bernard Zinman;John E. Gerich;John B. Buse;Andrew Lewin

  • Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes

    Michael Mauer;Bernard Zinman;Robert Gardiner;Samy Suissa

  • Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association.

    Sarah D. de Ferranti;Ian H. de Boer;Vivian Fonseca;Caroline S. Fox

  • Are Metabolically Healthy Overweight and Obesity Benign Conditions

    Caroline K. Kramer;Bernard Zinman;Ravi Retnakaran

Frequent Co-Authors

Anthony J.G. Hanley
Anthony J.G. Hanley University of Toronto
Philip W. Connelly
Philip W. Connelly University of Toronto
Stewart B. Harris
Stewart B. Harris University of Western Ontario
Robert A. Hegele
Robert A. Hegele University of Western Ontario
Christoph Wanner
Christoph Wanner University of Würzburg
Silvio E. Inzucchi
Silvio E. Inzucchi Yale University
John M. Lachin
John M. Lachin George Washington University
Subodh Verma
Subodh Verma University of Toronto
Steven E. Kahn
Steven E. Kahn University of Washington
John B. Buse
John B. Buse University of North Carolina at Chapel Hill

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Beyond traditional medical degrees, online programs offer flexible options for advancing your career in healthcare. For those seeking leadership roles in hospitals or healthcare organizations, consider online mha programs cahme accredited. These programs ensure high standards and open doors to management opportunities.

Registered nurses looking to upgrade their qualifications without extensive hands-on requirements may benefit from rn to bsn online programs without clinicals. Such pathways make it easier to fit studies around busy work schedules.

If rapid advancement is a priority, you can explore shortest dnp programs online designed to speed up your journey toward the highest levels of clinical practice or healthcare leadership—with completion times often under two years.

For cost-conscious professionals, researching the cheapest dnp program lets you enhance your credentials without a massive investment. Online pathways continue to evolve, offering a broad array of career opportunities within and beyond patient care.

Best Scientists Citing Bernard Zinman

Trending Scientists

Recently Published Articles